John Desjarlais

John Desjarlais leads scientific development at Xencor, where he created the XmAb bispecific antibody platform using engineered Fc domains that enable correct heavy chain heterodimerization and extended serum half-life for T cell-engaging bispecific antibodies. The XmAb platform has generated multiple clinical candidates including bispecific antibodies for hematologic and solid tumor malignancies. His work on Fc engineering has also produced cytokine-antibody fusion proteins and other bifunctional molecules with optimized pharmacological properties.